DDMoRe will present a free one day workshop on the 7th of June entitled
"Get inspired ... get started ... get into the world of DDMoRe".
This workshop will consist of presentations and hands-on session with DDMoRe
products and runs from 9:00 to 18:00 PM:
9:00 - 9:15 General introduction
9:15 - 9:45 Interoperability Framework introduction
9:45 - 10:15 Intro to Model Description Language (MDL)
coffee break
10:30 - 11:00 MDL continued
11:00 - 12:00 Interoperability Framework hands-on session
12:00 - 12:30 Exchange standards
Lunch
13:30 - 14:00 Model Repository, Qualification procedure and Annotations
14:00 - 15:00 Encoding models hands-on session
coffee break
15:15 - 16:45 Model Repository: browse / explore / download / use models
16:45 - 17:15 Introduction to workflow plus new tools
17:15 - 18:00 DDMoRe Foundation: What is the future for DDMoRe? Q&A
All these products together deliver the DDMoRe platform, which will be
demonstrated live with real model examples, showing the different elements and
intended workflows. The added value of the products to efficiently apply
model-based approaches and knowledge exchange - supporting the concept Model
Informed Drug Discovery and Development (MID3) - will be discussed in the
closing session of the workshop.
If you are interested please register to the workshop:
http://www.eventbrite.nl/e/ddmore-workshop-at-page-meeting-2016-registration-21005999510?ref=ebtn
For more information:
http://www.ddmore.eu/events/page-meeting-lisboa-portugal
________________________________
AstraZeneca UK Limited is a company incorporated in England and Wales with
registered number: 03674842 and a registered office at 2 Kingdom Street,
London, W2 6BD.
Confidentiality Notice: This message is private and may contain confidential,
proprietary and legally privileged information. If you have received this
message in error, please notify us and remove it from your system and note that
you must not copy, distribute or take any action in reliance on it. Any
unauthorised use or disclosure of the contents of this message is not permitted
and may be unlawful.
Disclaimer: Email messages may be subject to delays, interception, non-delivery
and unauthorised alterations. Therefore, information expressed in this message
is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by
an authorised representative independent of this message. No contractual
relationship is created by this message by any person unless specifically
indicated by agreement in writing other than email.
Monitoring: AstraZeneca UK Limited may monitor email traffic data and content
for the purposes of the prevention and detection of crime, ensuring the
security of our computer systems and checking compliance with our Code of
Conduct and policies.